Adenosine Receptor

Adenosine Receptor Related Products (297):

By Effects:	Inhibitors (24) Agonists (86) Antagonists (136) Activators (6) Modulators (8) Ligands (11)

Cat. No.	Product Name	Effect	Purity

HY-103173

5'-N-Ethylcarboxamidoadenosine	Agonist	99.09%
5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.

HY-13201A

CGS 21680 Hydrochloride	Agonist	99.70%
CGS 21680 Hydrochloride is a selective adenosine A2A receptor agonist with a K_i of 27 nM.

HY-19533

SCH 58261	Antagonist	99.71%
SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC₅₀ of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively.

HY-10888

Istradefylline	Antagonist	99.89%
Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with K_i of 2.2 nM in experimental models of Parkinson's disease.

HY-100937

DPCPX	Antagonist	99.96%
DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a K_i of 0.46 nM in ³H-CHA binding to A1 receptors in rat whole brain membranes.

HY-404647

FK3453	Inhibitor
FK3453 is a dual adenosine A1/A2 inhibitor and a TSLP inhibitor. FK3453 is also a substrate of aldehyde oxidase (AO). FK3453 can inhibit the production of TSLP and IL-33. FK3453 is useful for research on Parkinson’s disease and allergic disorders.

HY-108942

ASP5854	Antagonist
ASP5854 is an orally active, blood-brain barrier permeable adenosine A1/A2a dual receptor antagonist. ASP5854 blocks receptor activity and agonist-induced intracellular calcium elevation, and exhibits the characteristic of slow dissociation from striatal A2a receptors in primates. ASP5854 reverses catalepsy, enhances cognitive ability, improves motor function and exerts neuroprotective effects, while also alleviating dyskinesia and increasing contralateral turning behavior. ASP5854 is mainly used in studies related to ischemic stroke and Parkinson's disease.

HY-182782

Analgesic agent-4	Ligand
Analgesic agent-4 is an adenosine A₃AR ligand with analgesic/antinociceptive activity. Analgesic agent-4 inhibits writhing responses in mice and exhibits dose-dependent activity in the acetic acid (HY-Y0319)-induced mouse writhing model. Analgesic agent-4 can be used in the research of pain-related diseases.

HY-W010936

Nitrobenzylthioinosine		98.57%
Nitrobenzylthioinosine is an ENT1 transporter inhibitor that binds to ENT1 transporter with high affinity. Nitrobenzylthioinosine is a photoaffinity probe for adenosine uptake sites in brain. Nitrobenzylthioinosine can cross the blood-brain barrier.

HY-103171

BAY 60-6583	Agonist	99.93%
BAY 60-6583 is a potent and high-affinity agonist of adenosine A_2B receptor (EC₅₀=3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with K_i values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model.

HY-101978

Ciforadenant	Antagonist	99.85%
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses.

HY-103166

PSB-603	Antagonist	99.38%
PSB-603 is a potent and highly selective A_2B adenosine receptor antagonist exhibiting a K_i value of 0.553 nM and virtually no affinity for the human and rat A₁ and A_2A and the human A₃ receptors up to a concentration of 10 μM.

HY-129393

Etrumadenant	Antagonist	99.67%
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities.

HY-13591

Piclidenoson	Agonist	99.01%
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19.

HY-14121

MRS 1754	Antagonist	98.31%
MRS 1754 is a selective antagonist radioligand for A_2B adenosine receptor with very low affinity for A₁ and A₃ receptors of both humans and rats.

HY-N0138

Theobromine	Inhibitor	99.55%
Theobromine is a methylxanthine found in cacao beans which can inhibit adenosine receptor A1 (AR1) signaling.

HY-N0092S2

Inosine-¹³C₅	Agonist	99.90%
Inosine-¹³C₅ is the ¹³C₅ labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors.

HY-103181

N6-Cyclopentyladenosine	Agonist	99.95%
N6-Cyclopentyladenosine (CPA) is a selective Adenosine A₁ receptor agonist, with K_i values of 2.3 nM, 790 nM and 43 nM for human A₁, A_2A and A₃ receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures.

HY-A0168

Regadenoson	Agonist	99.59%
Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS.

HY-18939

N6-Cyclohexyladenosine	Agonist	99.98%
N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC₅₀ = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.